ENGULF Study Demonstrates Strong Safety and Efficacy for E2’s Hēlo™ Thrombectomy System in Pulmonary Embolism

Results from the pivotal cohort of the ENGULF Investigational Device Exemption (IDE) study evaluating Endovascular Engineering’s (E2) Hēlo™ Thrombectomy System were presented as a late-breaking clinical trial at the annual VIVA conference. The data showed that the system achieved both its primary safety and efficacy endpoints, underscoring its potential as a next-generation technology for pulmonary embolism (PE) treatment.

Study Overview

The ENGULF Study (NCT05597891) included 105 patients across 19 U.S. hospitals, with 40 physician operators from interventional cardiology, interventional radiology, and vascular surgery specialties. The study met its primary endpoints, demonstrating a 0.95% major adverse event rate at 48 hours and a 25.1% reduction in right ventricle/left ventricle (RV/LV) ratio, a key marker of heart strain in PE patients.

The Hēlo system also enabled single-pass clot removal and integrated workflow blood return capabilities, indicating potential procedural efficiency benefits.

Technology Innovation

The Hēlo Thrombectomy System features a 24F clot engagement zone with a 15F heart-crossing profile, combining high-power aspiration with advanced clot remodeling for targeted, large-vessel clot removal.

“E2 took a unique approach by evolving the catheter design throughout the pivotal study—arriving at a complete platform for PE treatment,” said Dr. Andrew Klein, National Co-Principal Investigator and interventional cardiologist at Piedmont Hospital, Atlanta.

“The results highlight the union of purpose-driven technology and clinical performance,” added Dr. Julie Bulman, Co-Principal Investigator from Beth Israel Deaconess Medical Center, Boston.

Clinical Context

Pulmonary embolism is a leading cause of cardiovascular mortality worldwide. The ENGULF pivotal results build upon findings from the earlier feasibility cohort, published in JSCAI (May 2024), and contribute to growing evidence supporting mechanical thrombectomy as a frontline intervention for high-risk PE.

E2 stated it will continue to collaborate with investigators and share additional data as part of its ongoing commitment to advancing venous thromboembolism (VTE) treatment.

About Endovascular Engineering (E2)

Endovascular Engineering, Inc. (E2) is a medtech innovator developing novel solutions for venous thromboembolism intervention. The company’s Hēlo™ platform integrates clinical insight with advanced engineering to improve outcomes in clot removal. The Hēlo Thrombectomy System is currently an investigational device and not yet FDA approved.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!